For Regeneron, Near-Term PCSK9 Filing, Eylea Growth Point To Rapidly Improving Prospects
This article was originally published in The Pink Sheet Daily
Executive Summary
Regeneron and partner Sanofi estimate there are more than 60 million addressable patients for LDL-lowering therapy in the U.S. and EU, including 22 million at very-high risk for a cardiovascular event. Meanwhile, a label addition for diabetic macular edema heightens the sales-growth prospects for Eylea.